Patents by Inventor Penelope Elizabeth Miller

Penelope Elizabeth Miller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor
    Publication number: 20080206257
    Abstract: The present invention relates to compositions and methods for treating the epithelial toxicity caused by administering to a human cancer patient an epidermal growth factor receptor (EGFR) inhibitor. The pharmaceutical composition preferably comprises an EGFR inhibitor and a keratinocyte growth factor (KGF) in a pharmaceutically-acceptable carrier. The method of treatment comprises co-administering to the patient a therapeutically effective amount of KGF with the EGFR inhibitor.
    Type: Application
    Filed: April 30, 2008
    Publication date: August 28, 2008
    Inventors: Penelope Elizabeth Miller, James Dale Moyer
  • Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor
    Patent number: 7402557
    Abstract: The present invention relates to compositions and methods for treating the epithelial toxicity caused by administering to a human cancer patient an epidermal growth factor receptor (EGFR) inhibitor. The pharmaceutical composition preferably comprises an EGFR inhibitor and a keratinocyte growth factor (KGF) in a pharmaceutically-acceptable carrier. The method of treatment comprises co-administering to the patient a therapeutically effective amount of KGF with the EGFR inhibitor.
    Type: Grant
    Filed: June 10, 2003
    Date of Patent: July 22, 2008
    Inventors: Penelope Elizabeth Miller, James Dale Moyer
  • Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor
    Publication number: 20040071697
    Abstract: The present invention relates to compositions and methods for treating the epithelial toxicity caused by administering to a human cancer patient an epidermal growth factor receptor (EGFR) inhibitor. The pharmaceutical composition preferably comprises an EGFR inhibitor and a keratinocyte growth factor (KGF) in a pharmaceutically-acceptable carrier. The method of treatment comprises co-administering to the patient a therapeutically effective amount of KGF with the EGFR inhibitor.
    Type: Application
    Filed: June 10, 2003
    Publication date: April 15, 2004
    Applicants: PFIZER PRODUCTS INC., OSI PHARMACEUTICALS, INC.
    Inventors: Penelope Elizabeth Miller, James Dale Moyer
  • Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor
    Publication number: 20020061304
    Abstract: The present invention relates to compositions and methods for treating the epithelial toxicity caused by administering to a human cancer patient an epidermal growth factor receptor (EGFR) inhibitor. The pharmaceutical composition preferably comprises an EGFR inhibitor and a keratinocyte growth factor (KGF) in a pharmaceutically-acceptable carrier. The method of treatment comprises co-administering to the patient a therapeutically effective amount of KGF with the EGFR inhibitor.
    Type: Application
    Filed: March 15, 2001
    Publication date: May 23, 2002
    Applicant: PFIZER PRODUCTS INC. & OSI PHARMACEUTICALS, INC.
    Inventors: Penelope Elizabeth Miller, James Dale Moyer